Addario Lung Cancer Medical Institute (ALCMI)

We accelerate investigator-led clinical trials. We pioneer solutions. We inspire hope. Get to know how we can help you with your research, and let's cure lung cancer together! #lungcancer #cancer #oncology

Roswell Park Comprehensive Cancer Center recently took a look back at 20 years of medical innovation and precision medicine. It's a must-read to see how far we've come. Twenty years ago, the discovery of the EGFR gene mutation transformed lung cancer treatment, heralding the era of precision medicine. This breakthrough allows doctors to tailor treatments to a patient’s genetic profile, significantly improving outcomes. “The discovery of the EGFR mutation was the start of precision medicine for lung cancer treatment,” Dr. Grace Dy. “It meant that we could now choose a specific drug for a patient based on their cancer’s unique molecular profile which increases the likelihood of treatment response compared to conventional chemotherapy.” Initially, drugs like gefitinib and erlotinib had mixed results until it was discovered that they were highly effective for patients with an EGFR mutation. This revelation emphasized the value of genetic testing in treatment plans and led to the development of new targeted therapies. Read more about precision medicine in lung cancer and what trials Roswell currently has in the works. #lungcancer #precisionmedicine https://lnkd.in/grcApccU

Our consortium member Northside Hospital's Dr. Akhil Vallabhaneni recently wrote an article about lung nodules and the importance of early detection. Lung nodules can be a silent precursor to lung cancer, which often goes unnoticed due to lack of symptoms. Early detection through screening could literally save lives. Dr. Vallabhaneni recommends that people in the recommended age group with a history of smoking should talk to their doctors about low-dose CT screening. Read more here. #lungcancer #lungnodules #earlydetection https://lnkd.in/gTj36jTQ

DocWire News reported that Deborah Brown, Chief Mission Officer for the American Lung Association, joined Lung Cancers Today to discuss the association’s latest “State of Lung Cancer” report and key findings. One of the major findings of the report is that over the past five years, the national average 5-year survival rate for lung cancer increased by 26%. Brown said she believes this is related to multiple factors, including expanded screening eligibility, advancements in research, and biomarker testing. For the first time, this year’s report examined insurance coverage of comprehensive biomarker testing across the US. “Insurance coverage for this is extremely important because it removes the cost barrier so that people with lung cancer can get the biomarker testing,” Brown said. “But right now, coverage for biomarker testing is only required in some states. The ‘State of Lung Cancer’ report found that only 15 states require insurance coverage for comprehensive biomarker marker testing, 5 states require some plans to cover it, and there are 30 states and Washington, DC, that have yet to require any type of coverage for this biomarker testing.” To address this, the American Lung Association is “calling for all states to implement policies to require insurance coverage of comprehensive biomarker testing,” she said. Check out the article and video here. #lungcancer #biomarkertesting #americanlungassociation https://lnkd.in/gJ-4Pgx2

A new study provides a novel insight into small cell lung cancer (SCLC). Published in Science Direct, researchers have discovered that the long non-coding RNA MACC1-AS1 plays a crucial role in the growth of SCLC cells. By sequestering miR-579-3p and mediating the NOTCH1 pathway, MACC1-AS1 facilitates cancer cell proliferation, providing a potential new target for therapy. Dr. Jiang Hong and colleagues have shown that knocking down MACC1-AS1 significantly hinders the growth and migration of SCLC cells by inducing apoptosis. This groundbreaking research could pave the way for innovative treatments for patients with SCLC, a notoriously aggressive form of cancer. Understanding the mechanisms at play opens the door to developing more effective diagnostic and therapeutic strategies. For those interested in diving deeper into the science, you can read the full study on ScienceDirect here. https://lnkd.in/gCtPmZBs

Exciting news from Cofactor Genomics! They have just announced the validation and launch of OncoPrism?-NSCLC, an RNA-based diagnostic tool designed to predict patient responses to immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC). This breakthrough follows the recent Medicare coverage approval for their OncoPrism-HNSCC test, expanding the potential benefits of precision medicine. “OncoPrism-NSCLC dramatically expands the number of patients who can benefit from OncoPrism testing, as NSCLC patients are the largest patient population being treated with ICI," said Dr. Jarret Glasscock, CEO of Cofactor Genomics. "This launch is another important step in achieving Cofactor’s goal of bringing precision medicine to all cancer patients.” Check out the press release on BioSpace here. #lungcancer #oncology #nsclc https://lnkd.in/gnehB67D

At ALCMI, one of the pillars of our research efforts is to uncover the mystery of why younger people are contracting lung cancer. It's an urgent issue. Recently, our consortium partner City of Hope wrote an article about a rising trend in lung cancer among nonsmoking Asian women in their 40s and 50s. It’s a story that’s both heartbreaking and inspiring, shedding light on the urgent need for improved screening and early detection. City of Hope thoracic surgeon Dr. Jae Kim has been researching this phenomenon for years. He notes that two-thirds of these cancers in Asian women display the EGFR mutation, likely influenced by genetic and environmental factors such as air pollution and secondhand smoke. Dr. Kim emphasizes the importance of early detection, which is unfortunately not widely available in the U.S. for nonsmokers. Read the full article here. #lungcancer #efgr #oncology https://lnkd.in/gfTERjCk

An exciting update from UVA Cancer Center! They recently became the first in Virginia to offer lung cancer patients tarlatamab, a new immunotherapy drug approved in May. This drug is set to supercharge the immune system to fight small-cell lung cancer when combined with chemotherapy. Dr. Ryan G., a thoracic medical oncologist at UVA Health, shared insights on this breakthrough, emphasizing the center's robust clinical trial program. "Some of these trials are early phase, developing brand-new drugs, while others are later-phase trials that have the potential to change the standard of care and get an FDA approval," he said. Dive into the full story on UVA Today here. #lungcancer #immunotherapy #tarlatamab https://lnkd.in/ebQ2T3fV

Wow, interesting research that takes a new angle on lung cancer treatment! Researchers at the National University of Singapore, led by Assistant Professor Minh Le , are repurposing nano-sized particles from red blood cells to deliver antisense oligonucleotide (ASO) molecules directly to lung cancer cells. This approach not only targets and suppresses cancer progression but also addresses drug resistance, a major challenge in treating non-small cell lung cancer. You can dive into the full story on ScienceDaily. #lungcancer #medicalinnovation #nsclc https://lnkd.in/detvwjtk

With cold and flu season upon us, the?American Cancer Society?has released an article about the intersection of lung cancer and flu season. Dr. Charu Aggarwal shared some crucial advice for lung cancer patients during this time. Dr. Aggarwal emphasized that lung cancer patients are at a higher risk for respiratory illnesses like the flu due to their compromised immune systems. The doctor advised patients to take preventive measures such as getting vaccinated, practicing good hygiene, and avoiding crowded places. It's a must-read for anyone looking to understand how to better protect themselves or loved ones during the flu season. You can find the full article here. #lungcancer #fluseason https://lnkd.in/gpFxMyrY